Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Aký ticker má akcia spoločnosti Catabasis Pharmaceuticals?▼
Ticker akcie sa môže líšiť podľa burzy. Napríklad na burze Boerse Muenchen sa akcie spoločnosti Catabasis Pharmaceuticals obchodujú pod tickerom 209A.MU.
Koľko má Catabasis Pharmaceuticals zamestnancov?▼
Ku dňu júla 09, 2026 má spoločnosť 78 zamestnancov.
Do akého sektora patrí Catabasis Pharmaceuticals?▼
Catabasis Pharmaceuticals pôsobí v sektore Health & Wellness.
Kedy spoločnosť Catabasis Pharmaceuticals uskutočnila split akcií?▼
Spoločnosť Catabasis Pharmaceuticals v poslednom čase neuskutočnila žiadny split akcií.
Kde má Catabasis Pharmaceuticals sídlo?▼
Catabasis Pharmaceuticals má sídlo v meste Boston, Spojené štáty.